<DOC>
	<DOCNO>NCT00480753</DOCNO>
	<brief_summary>The purpose clinical study determine response two different dosage strength topical nitroglycerin gel patient Raynaud 's Phenomenon . Patient finger monitor change blood flow skin temperature . Symptoms pain , tingle numbness also monitor .</brief_summary>
	<brief_title>Dose Response Study Topical Formulation Nitroglycerin Treatment Raynaud 's Phenomenon</brief_title>
	<detailed_description>It intention protocol study , control manner , response finger patient Raynaud 's phenomenon two dosage strength fast act topical formulation Nitroglycerin , MQX-503 . Patients may moderate severe primary Raynaud 's phenomenon Raynaud 's phenomenon secondary autoimmune disease scleroderma . Quantitative change blood flow finger non-dominant hand measure clinical induction constriction blood vessel exposure local cold temperature . Secondarily , quantitative reduction skin temperature recovery time symptom pain , tingle numbness associate Raynaud 's phenomenon evaluate use patient hand symptom analog assessment score . The frequency severity adverse event associate MQX-503 assess .</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>Patients Raynaud 's phenomenon Patients willing discontinue current therapy Raynaud 's phenomenon The use medication contain nitroglycerin know interact nitroglycerin Patients history migraine severe headache Open skin lesion skin condition area medication apply Pregnant nurse woman wish become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Raynaud 's phenomenon</keyword>
	<keyword>Raynaud 's Disease</keyword>
	<keyword>Raynaud 's disease secondary scleroderma</keyword>
	<keyword>Raynaud 's phenomenon secondary autoimmune disease</keyword>
</DOC>